{"Clinical Trial ID": "NCT00546104", "Intervention": ["INTERVENTION 1:", "Dasatinib", "- 50mg-100mg in BID"], "Eligibility": ["Incorporation criteria:", "\u2022 Measurable level IV or inoperable stage III advanced breast cancer.", "There is no limit to the number of previous therapies.", "At least 3 weeks since prior chemotherapy, biological or hormonal treatment.", "At least 2 weeks after surgical biopsy.", "At least 3 weeks after major surgery (thoracic/abdominal/opencardiac).", "No central nervous system (CNS) metastases except solitary brain metastases", "No cardiac dysfunction", "The left ventricular ejection fraction (LVEF) is 50% determined by a multiple-access acquisition scan (MUGA)/echocardiogram", "A proper blood count", "Normal function of the liver and kidneys", "Negative serum pregnancy test.", "Able to give informed consent", "- Exclusion criteria:", "Pregnant or breast-feeding.", "Previous treatment with dasatinib.", "The bones are the only site of the disease.", "Significant gastrointestinal haemorrhage", "Septicaemia, infection, acute hepatitis, hypokalaemia or hypomagnesaemia"], "Results": ["Performance measures:", "Estimated proportion of patients without progression at 16 Wks.", "The progression is defined using the criteria for assessing response in solid tumours (RECIST v1.0), such as a 20% increase in the sum of the longest diameter of the target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, or a similar definition as the case may be.", "From the first day of treatment with Dasatinib to the date of first documented progression or date of death of any cause, whichever occurs first.", "Time limit: 16 weeks", "Results 1:", "Title of the arm/group: Dasatinib", "Description of the arm/group: 50mg-100mg in BID", "Total number of participants analysed: 31", "Type of measurement: Number", "Unit of measure: % of participants 0 (0-20)"], "Adverse Events": ["Undesirable Events 1:", "Total: 10/31 (32.26 per cent)", "1/31 (3.23%)", "Thrombosis1/31 (3.23%)", "Diarrhoea1/31 (3.23%)", "- Pain 2/31 (6.45%)", "Pain, back1/31 (3.23%)", "1/31 (3.23%)", "- Syncope 1/31 (3.23%)", "Pain, chest/thorax1/31 (3.23%)", "Hyponatraemia 1/31 (3.23%)", "- Fever1/31 (3.23%)", "AST 1/31 (3.23%)", "Infection1/31 (3.23%)", "Anorexia 1/31 (3.23%)", "Dyspnoea 2/31 (6.45%)"]}